Markia A. Smith

Markia A. Smith

Auto-generated profile, based on publicly available information

Markia A. Smith

Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SGSusana Garcia-Recio
Susana Garcia-Recio
THToshinori Hinoue
Toshinori Hinoue
GWGregory L. Wheeler
Gregory L. Wheeler
BKBenjamin J. Kelly
Benjamin J. Kelly
AGAna C. Garrido-Castro
Ana C. Garrido-Castro
CPCharles M Perou
Charles M Perou
The AURORA US Metastasis Project was established with the goal to identify molecular features associated with metastasis. We assayed 55 females with metastatic breast cancer (51 primary cancers and 102 metastases) by RNA sequencing, tumor/germline DNA exome and low-pass whole-genome sequencing and global DNA methylation microarrays. Expression subtype changes were observed in ~30% of samples and were coincident with DNA clonality shifts, especially involving HER2. Downregulation of estrogen receptor (ER)-mediated cell–cell adhesion genes through DNA methylation mechanisms was observed in metastases. Microenvironment differences varied according to tumor subtype; the ER+/luminal subtype had lower fibroblast and endothelial content, while triple-negative breast cancer/basal metastases showed a decrease in B and T cells. In 17% of metastases, DNA hypermethylation and/or focal deletions were identified nearHLA-Aand were associated with reduced expression and lower immune cell infiltrates, especially in brain and liver metastases. These findings could have implications for treating individuals with metastatic breast cancer with immune- and HER2-targeting therapies.

11 June 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JDJeffrey Damrauer
Jeffrey Damrauer
KRKyle R. Roell
Kyle R. Roell
MSMarkia A. Smith
Markia A. Smith
XSXuezheng Sun
Xuezheng Sun
EKErin L. Kirk
Erin L. Kirk
EPEugene J. Pietzak
Eugene J. Pietzak
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for non–muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC. Experimental Design: Gene expression in NMIBC samples was profiled by NanoString nCounter, an RNA quantification platform, from two independent cohorts (n = 28, n = 50); targeted panel sequencing was performed in a subgroup (n = 50). Gene signatures were externally validated using two RNA sequencing datasets of NMIBC tumors (n = 438, n = 73). Established molecular subtype classifiers and novel gene expression signatures were assessed for associations with clinicopathologic characteristics, somatic tumor mutations, and treatment outcomes. Results: Molecular subtypes distinguished between low-grade Ta tumors with FGFR3 mutations and overexpression (UROMOL-class 1) and tumors with more aggressive clinicopathologic characteristics (UROMOL-classes 2 and 3), which were significantly enriched with TERT promoter mutations. However, UROMOL subclasses were not associated with recurrence after bacillus Calmette-Guérin (BCG) immunotherapy in two independent cohorts. In contrast, a novel expression signature of an inflamed tumor microenvironment (TME) was associated with improved recurrence-free survival after BCG. Expression of immune checkpoint genes (PD-L1/PD-1/CTLA-4) was associated with an inflamed TME, but not with higher recurrence rates after BCG. FGFR3 mutations and overexpression were both associated with low immune signatures. Conclusions: Assessment of the immune TME, rather than molecular subtypes, is a promising predictive biomarker of BCG response. Modulating the TME in an immunologically “cold” tumor warrants further investigation. Integrated transcriptomic and exome sequencing should improve treatment selection in NMIBC.

15 July 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MGMaya L. Gosztyla
Maya L. Gosztyla
LKLydia Kwong
Lydia Kwong
NMNaomi A. Murray
Naomi A. Murray
CWClaire E. Williams
Claire E. Williams
NBNicholas Behnke
Nicholas Behnke
MYMegan A. Yamoah
Megan A. Yamoah

21 September 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
AWAndrea Walens
Andrea Walens
SASarah C. Van Alsten
Sarah C. Van Alsten
LOLinnea T. Olsson
Linnea T. Olsson
MSMarkia A. Smith
Markia A. Smith
ALAlex Lockhart
Alex Lockhart
MTMelissa A. Troester
Melissa A. Troester
Background: Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied. Methods: To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes. Results: : Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78). Conclusions: HRD is associated with poor prognosis and enriched in the tumors of black women. Impact: RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.

4 October 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
JDJeffrey Damrauer
Jeffrey Damrauer
MSMarkia A. Smith
Markia A. Smith
VWVonn Walter
Vonn Walter
ATAatish Thennavan
Aatish Thennavan
LMLisle E. Mose
Lisle E. Mose
KHKatherine A Hoadley
Katherine A Hoadley
Primary liver cancer, consisting of both cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC), is the second leading cause of cancer deaths worldwide. Our goal is to genomically characterize rare HCC subclasses to provide insight into disease biology. Leveraging The Cancer Genome Atlas (TCGA) to perform a combined analysis of CCA (n = 36) and HCC (n = 275), we integrated multiple genomic platforms, to assess transcriptional profiles, mutational signatures, and copy number patterns to uncover underlying etiology and linage specific patterns. We identified two molecular classes distinct from prototypical HCC tumors. The first, CCA-Like, although histologically indistinguishable from HCC, had enrichment of CCA mutations (IDH1,BAP1), mutational signatures, and transcriptional patterns (SOX9,KRT19). CCA-Like, however, retained a copy number landscape similar to HCC, suggesting a hepatocellular linage. The second, Blast-Like, is enriched inTP53mutations, HBV infection, exposure related mutational signatures and transcriptionally similar to hepatoblasts. Although these subclasses are molecularly distinct, they both have a worse progression-free survival compared to classical HCC tumors, yet are clinically treated the same. The identification of and characterization of CCA-Like and Blast-Like subclasses advance our knowledge of HCC as well as represents an urgent need for the identification of class specific biomarkers and targeted therapy.

8 March 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DMDaphne Oluwaseun Martschenko
Daphne Oluwaseun Martschenko
MSMarkia Smith
Markia Smith